Mason Street Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mason Street Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-58,620	Closed	-$5.69M	–	1521
2014 Q4	$5.69M	Sell	58,620 -300	-0.5%	-$27.8K	0.04%	503
2014 Q3	$4.6M	Sell	58,920 -6,610	-10%	-$426K	0.04%	543
2014 Q2	$4.14M	Buy	65,530 +6,380	+11%	+$379K	0.03%	623
2014 Q1	$3.97M	Sell	59,150 -4,930	-8%	-$382K	0.03%	611
2013 Q4	$4.12M	Buy	64,080 +4,780	+8%	+$285K	0.03%	591
2013 Q3	$3.8M	Buy	+59,300	New	+$2.96M	0.04%	445

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mason Street Advisors's ALNY Position: Q1 2015 in Review

Mason Street Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2015, closing a stake of 58,620 shares — an estimated $5.69M sold.

Mason Street Advisors first reported a position in ALNY in Q3 2013 and held it in 6 quarters. The position peaked at $5.69M in Q4 2014. 238 funds tracked by Wall St. Rank hold ALNY as of Q1 2015.

Mason Street Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 58,620 Alnylam Pharmaceuticals shares in Q1 2015, an estimated $5.69M.
Mason Street Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Mason Street Advisors's Alnylam Pharmaceuticals position peaked at $5.69M in Q4 2014.
238 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.